Capital layer
Who could finance the programme
- Private investors
- Strategic capital
- Impact capital
- Potential digital rails
- Milestone-linked capital deployment
DeSci infrastructure for regulated clinical development
NWPharmaTech is exploring a ring-fenced programme-financing model for its CHR-P development programme, combining regulated private capital, milestone accountability and digital transparency while preserving conventional pharmaceutical governance.
Exploratory programme architecture. Not an offer or solicitation.
Decentralised capital. Centralised clinical responsibility.
How a ring-fenced structure could move capital toward a defined clinical step, with NWPharmaTech inside a protected sponsor boundary. The structure is under evaluation; nothing on this path is live.
Eligible investors and partners, through private conversations only. Nothing is raised on this website.
A proposed vehicle limited to expressly granted CHR-P programme economics, separate from NWPharmaTech parent equity.
Bank or custody accounts with dual-control release against operational milestones, not efficacy claims.
Sponsor boundary
Remains the pharmaceutical sponsor: protocol, dose, endpoints, safety, CMC, regulatory filings and core IP.
Preparation and start-up work toward the proposed Phase 2B, subject to financing and approvals.
Progress and use of funds reported against agreed operational milestones. The verification method is part of the structure under evaluation.
Readiness for the proposed Phase 2B: an operational step, not an efficacy or prevention result.
Architecture
Capital layer
Transparency layer
Sponsor layer · protected clinical boundary
Eligibility criteria remain within the sponsor-approved protocol. Individual participant eligibility is determined by investigators/sites under the protocol and applicable oversight.
Investigators, ethics committees and regulators remain independent.
The line we hold
Blockchain should record accountability, not practice medicine.
Capital supporters do not vote on clinical design, trial budget or sponsor decisions. Transparent financing does not mean decentralised clinical governance.
Process
A qualified investor or partner begins a private discussion.
Science, programme, use of funds and proposed structure are reviewed.
The legal instrument and programme-specific contractual rights are defined privately.
Applicable KYC, investor and jurisdiction checks are completed.
A conventional private closing; a permissioned digital record may be added where feasible.
Capital deployment and programme progress are reported against agreed milestones.
Instrument, economic rights, jurisdictions and digital-record architecture remain under evaluation. Conventional register-first private placement remains available as the fallback.
The next financing objective
Synopsis and protocol path, CRO selection and study start-up.
First-site readiness when approvals allow. No one is being recruited.
Investigational product readiness for a start window.
Ethics and regulatory start-up work.
Programme management, contingency and controlled wind-down capacity.
Data management, analysis planning and programme reporting.
Not presented as the full cost of global Phase 2B. A bottoms-up RFQ and use-of-proceeds exercise is being developed. The target is a planning assumption, not a Board-approved budget.
Why digital rails?
Digital infrastructure could support five potential capabilities. None of them is operating today. Subject to legal, technical and operating diligence.
Could provide durable records of programme milestones and reporting.
Could support milestone-linked controls around capital deployment.
Could help different categories of sophisticated capital participate around one programme.
Could make progress easier to follow without disclosing confidential patient, regulatory or IP information.
Could automate permitted administrative and reporting functions, while clinical decisions remain off-chain.
Programme status
Plain answers
Early-intervention CHR-P research often needs careful, long studies that conventional venture timelines struggle to match. The aim is for specialist life-sciences capital and newer constituencies — including crypto-native family offices and mission-aligned DeSci supporters — to sit around a clear programme plan without weakening sponsor accountability.
No. There is no live public offering, no public token sale, no token allocation, no payment rail, no minting and no staking on this website. You cannot invest, pay or connect a wallet here.
No. No yield, liquidity or appreciation is promised. There is no price chart. Any economic rights, if ultimately offered, would arise only under definitive private documentation, applicable eligibility requirements and applicable law. The instrument, economics, jurisdictions and structure remain under evaluation; nothing is final.
No. Approximately US$10m is the current planning target for catalytic preparation and start-up toward the proposed Phase 2B. It is not presented as the full cost of Phase 2B; the detailed RFQ and bottoms-up use-of-proceeds exercise is still in development.
No. There is no tokenholder clinical governance. NWPharmaTech keeps sponsor authority and responsibility for the protocol, dose and endpoints, safety, CMC and manufacturing, regulatory submissions, IP, counterparties, and licensing and commercial decisions. Eligibility criteria remain within the sponsor-approved protocol. Individual participant eligibility is determined by investigators/sites under the protocol and applicable oversight. Investors would not own the medicine or patient data.
A permissioned digital record at close is being evaluated where it is legally and operationally useful: to record accountability and reporting, not to make clinical decisions. If it is not feasible, a conventional register-first private placement remains the fallback. The legal investor register is the record of truth: any permissioned digital representation, if used, would only mirror it. Providers and timing remain under evaluation.
Yes. Most visitors are not investors, and should not need to be. You can read the science, follow updates, and send research or collaboration enquiries; see Community. Community follow or membership is not an investment entitlement, and community updates and discussion are separate from any regulated investment process.
No public data room. Diligence materials, where appropriate, are shared privately after a conversation.
Explore the programme
The purpose of programme financing is to fund a clearly defined next clinical step while making uncertainty, accountability and sponsor responsibility explicit.
Exploratory information only. No investment, token or allocation is being offered through this website.
Last reviewed: 30 September 2026